<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02387216</url>
  </required_header>
  <id_info>
    <org_study_id>MM-121-01-02-09</org_study_id>
    <nct_id>NCT02387216</nct_id>
  </id_info>
  <brief_title>A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC</brief_title>
  <official_title>A Phase 2 Study of MM-121 in Combination With Docetaxel or Pemetrexed Versus Docetaxel or Pemetrexed Alone in Patients With Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merrimack Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merrimack Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the combination of MM-121 plus docetaxel
      or pemetrexed is more effective than docetaxel or pemetrexed alone in regards to OS in
      patients with heregulin-positive NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, open-label, international, multi-center, phase 2 study in
      patients with Heregulin-positive NSCLC that have progressed following no more than three
      systemic therapies for locally advanced or metastatic disease, of which one must have been a
      platinum based doublet therapy. All patients will initially be screened for heregulin
      status. Eligible patients will be randomized to receive MM-121 in combination with
      investigator's choice of either docetaxel or pemetrexed versus docetaxel or pemetrexed
      alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time from randomization to death, approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Time from randomization to progression, approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disease status will be assessed according to RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Independent Central Review - PFS</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events reported with the combination of MM-121 with docetaxel or pemetrexed</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess health-related quality of life (HRQOL) in NSCLC</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters of MM-121 in combination with docetaxel or pemetrexed and of docetaxel and pemetrexed when given in combination with MM-121.</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>NSCLC</condition>
  <condition>Adenocarcinoma</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Heregulin</condition>
  <condition>Large Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A: Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MM-121 in combination with either Docetaxel or Pemetrexed (Investigator's choice)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Comparator Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel or Pemetrexed (Investigator's choice) alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MM-121</intervention_name>
    <description>Investigational, fully human antibody targeting and inhibiting ErbB3</description>
    <arm_group_label>Arm A: Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>approved chemotherapy treatment for NSCLC</description>
    <arm_group_label>Arm A: Experimental Arm</arm_group_label>
    <arm_group_label>Arm B: Comparator Arm</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>approved chemotherapy treatment for NSCLC</description>
    <arm_group_label>Arm A: Experimental Arm</arm_group_label>
    <arm_group_label>Arm B: Comparator Arm</arm_group_label>
    <other_name>ALIMTA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of cytologically or histologically confirmed NSCLC with
             either metastatic disease (stage IV) or Stage IIIB disease not amenable to surgery
             with curative intent

          -  Failed one prior platinum-based regimen and has not received more than 3 prior
             systemic therapies for primary or recurrent disease

          -  Received nivolumab or other approved anti-PD-1 or anti-PD-L1 therapy where available
             and clinically indicated

          -  Tissue submitted for HRG-biomarker testing

          -  ECOG performance status (PS) of 0 or 1

        Exclusion Criteria:

          -  Known ALK mutation

          -  Presence of exon 19 deletion or exon 21 (L858R) substitution of the EGFR gene

          -  Received &gt;3 prior systemic anti-cancer drug regimen for locally advanced disease

          -  Prior treatment with an anti-ErbB3 antibody

          -  CTCAE grade 3 or higher peripheral neuropathy

          -  Symptomatic CNS metastases or CNS metastases requiring steroids

          -  Any other active malignancy requiring systemic therapy

          -  Clinically significant cardiac disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MM-121 Program Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merrimack Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Plezia, PharmD</last_name>
      <phone>(520) 290-2510</phone>
      <email>pplezia@acrcresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Nieva, MD</last_name>
      <phone>323.865.0421</phone>
      <email>Jorge.Nieva@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Young</last_name>
      <phone>707-521-3814</phone>
      <email>kimberly.young@stjoe.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Akar</last_name>
      <phone>813-745-4625</phone>
      <email>angela.akar@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Hoyer</last_name>
      <phone>312-695-1341</phone>
      <email>amy.hoyer@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Livia Szeto</last_name>
      <phone>773-834-0783</phone>
      <email>lszeto@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wael Harb, MD</last_name>
      <phone>765-446-5111</phone>
      <email>wharb@horizonbioadvance.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lecia Sequist, MD</last_name>
      <phone>617-724-4000</phone>
      <email>lvsequist@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Beth Kennedy</last_name>
      <phone>617-724-1223</phone>
      <email>eakennedy@partners.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiying Cheng, MD</last_name>
      <phone>7184058539</phone>
      <email>hcheng@montefiore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Hull, RN</last_name>
      <phone>212-731-5111</phone>
      <email>Jennifer.Hull@nyumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mara Yerk</last_name>
      <phone>412.578.5393</phone>
      <email>myerk@wpahs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misty Moore</last_name>
      <phone>615-524-4397</phone>
      <email>Misty.Moore@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VICC Clinical Trials Reporting Program</last_name>
      <phone>800-811-8480</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Tennessee</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Lee</last_name>
      <phone>215-728-2586</phone>
      <email>John.Lee@fccc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Chocquette, RN</last_name>
      <phone>571-389-0873</phone>
      <email>karin.choquette@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila Ponce</last_name>
      <phone>206-342-6926</phone>
      <email>leila.ponce@virginiamason.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Estacio</last_name>
      <phone>(416) 581-7804</phone>
      <email>Antonio.Estacio@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Munchen</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Borgmeier, M.D.</last_name>
      <phone>0049 89 4400 55393</phone>
      <email>astrid.borgmeier@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Regine Zauber</last_name>
      <phone>004989 440057612</phone>
      <email>Regine.zauber@med.uni-muenchen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Foellmer</last_name>
      <phone>+49 30 450 553 044</phone>
      <email>Ulrike.foellmer@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Moran</last_name>
      <email>mmoran@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Majahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belen Ruiz-Larrea</last_name>
      <phone>+34 911917418</phone>
      <email>bruizlarrea@idiphim.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enriqueta Felip, M.D.</last_name>
      <phone>+34932746085</phone>
      <email>efelip@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Florez</last_name>
      <phone>+ 34914269393</phone>
      <email>sandraflorez.hgugm@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel del Amo</last_name>
      <phone>917277516</phone>
      <email>raquel.amo.olivares@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Isabel Calderon</last_name>
      <phone>917277516</phone>
      <email>isabel.m.calderon@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Rojas</last_name>
      <phone>34951291425</phone>
      <email>ensayosch@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jose Bardina</last_name>
      <phone>+34 976 76 57 69</phone>
      <email>mjbardina.iacs@aragon.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 7, 2016</lastchanged_date>
  <firstreceived_date>February 12, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>heregulin</keyword>
  <keyword>ErbB3</keyword>
  <keyword>docetaxel</keyword>
  <keyword>pemetrexed</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Large Cell</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
